LB Pharmaceuticals Inc
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from LB Pharmaceuticals Inc's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-118.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 84% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-48.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 72% of Healthcare companies in United States.
Cash Cushion Ratio
+23%Cash, after subtracting all debt, equals 23% of its market value (net cash).
Higher than 65% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
LB Pharmaceuticals Inc owes $0.08 for every $1 it owns. LB Pharmaceuticals Inc made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
394.2Investors pay $394.2 for every $1 of LB Pharmaceuticals Inc's yearly profit, higher than 98% of Healthcare companies in United States.
P/B ratio
3.83The share price is 3.83 times LB Pharmaceuticals Inc's book value per share, higher than 64% of Healthcare companies in United States.
Market cap
$1.3 BThe total market value of all of LB Pharmaceuticals Inc's shares at today's price (share price × number of shares), larger than 67% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$332 MWhat LB Pharmaceuticals Inc would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$10.30Net worth divided by the number of shares. The share price of $39.42 is 3.8 times this, which is the P/B above.
Return on equity (ROE)
-50.0%LB Pharmaceuticals Inc lost 50.0% of its shareholders' money over the last year, lower than 51% of Healthcare companies in United States.
Owes vs Owns
0.08×LB Pharmaceuticals Inc owes $0.08 for every $1 it owns (low), lower than 90% of Healthcare companies in United States.
Dividend yield
NoneLB Pharmaceuticals Inc does not currently pay a dividend.
Profit growth
LossLB Pharmaceuticals Inc made a loss in each of the last two years.
Cash vs debt
Net cashLB Pharmaceuticals Inc held $292 M more cash than debt (net cash) at Dec 2025.
Questions
What is LB Pharmaceuticals Inc's P/E ratio?
Investors pay $394.2 for every $1 of LB Pharmaceuticals Inc's yearly profit, higher than 98% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For LB Pharmaceuticals Inc: $1.3 B ÷ $332 M (30 Jun 2026) = 3.8.
What is LB Pharmaceuticals Inc's return on equity?
LB Pharmaceuticals Inc lost 50.0% of its shareholders' money over the last year, lower than 51% of Healthcare companies in United States.
How much does LB Pharmaceuticals Inc owe compared with what it owns?
LB Pharmaceuticals Inc owes $0.08 for every $1 it owns (low), lower than 90% of Healthcare companies in United States.
Does LB Pharmaceuticals Inc pay a dividend?
No. LB Pharmaceuticals Inc does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.